# Ensysce Biosciences, Inc.: overview ENSC · Nasdaq · CIK 1716947 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ensc.md) · [Financials](/companies/ensc/financials.md) · [Filings](/companies/ensc/filings.md) · [Insiders](/companies/ensc/insiders.md) Latest reported revenue: [$1.2m](/filings/0001493152-26-037817.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037817). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,419](/filings/0001493152-25-023498.md) | [1,304 d](/filings/0001493152-26-013633.md) | [1,320](/filings/0001493152-26-023811.md) | [1,371](/filings/0001493152-26-037817.md) | [493](/filings/0001493152-25-023498.md) | [1,882 d](/filings/0001493152-26-013633.md) | [961](/filings/0001493152-26-023811.md) | [1,164](/filings/0001493152-26-037817.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [18.9%](/filings/0001493152-25-023498.md) | [(274.3%) d](/filings/0001493152-26-013633.md) | [(149.1%)](/filings/0001493152-26-023811.md) | [(127.6%)](/filings/0001493152-26-037817.md) | [(758.7%)](/filings/0001493152-25-023498.md) | [(147.8%) d](/filings/0001493152-26-013633.md) | [(370.7%)](/filings/0001493152-26-023811.md) | [(221.3%)](/filings/0001493152-26-037817.md) | | Net margin | % | [19.4%](/filings/0001493152-25-023498.md) | [(273.4%) d](/filings/0001493152-26-013633.md) | [(147.4%)](/filings/0001493152-26-023811.md) | [(126.4%)](/filings/0001493152-26-037817.md) | [(756.3%)](/filings/0001493152-25-023498.md) | [(147.0%) d](/filings/0001493152-26-013633.md) | [(370.1%)](/filings/0001493152-26-023811.md) | [(220.8%)](/filings/0001493152-26-037817.md) | | Diluted EPS | $ per share | [1.00](/filings/0001493152-25-023498.md) | not reported | [(1.39)](/filings/0001493152-26-023811.md) | [(0.79)](/filings/0001493152-26-037817.md) | [(1.29)](/filings/0001493152-25-023498.md) | not reported | [(0.52)](/filings/0001493152-26-023811.md) | [(0.20)](/filings/0001493152-26-037817.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | [(1,526) d](/filings/0001493152-26-013633.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,531](/filings/0001493152-23-009844.md) | [2,523](/filings/0001493152-24-009993.md) | [2,231](/filings/0001493152-25-009703.md) | [5,210](/filings/0001493152-26-013633.md) | [5,067](/filings/0001493152-26-013633.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(562.7%)](/filings/0001493152-23-009844.md) | [(959.9%)](/filings/0001493152-24-009993.md) | [(480.5%)](/filings/0001493152-25-009703.md) | [(129.2%)](/filings/0001493152-26-013633.md) | [(202.1%)](/filings/0001493152-26-013633.md) | | Net margin | % | [(825.4%)](/filings/0001493152-23-009844.md) | [(959.3%)](/filings/0001493152-24-009993.md) | [(476.4%)](/filings/0001493152-25-009703.md) | [(153.3%)](/filings/0001493152-26-013633.md) | [(200.8%)](/filings/0001493152-26-013633.md) | | Diluted EPS | $ per share | [(1.48)](/filings/0001493152-22-008438.md) | [(139.42)](/filings/0001493152-24-009993.md) | [(70.40)](/filings/0001493152-25-009703.md) | [(11.45)](/filings/0001493152-26-013633.md) | [(3.98)](/filings/0001493152-26-013633.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(7,930)](/filings/0001493152-26-013633.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ensc/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2020-06-19 | [Morgan Stanley](/insiders/895421.md) | 10% owner | Sale (S) | 776,290 | not reported | not reported | [Form 4](/filings/0000925421-20-000259.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $60.6k | 208,833 | | Added +195,263 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $43.4k | 149,711 | | Unchanged | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $25.1k | 86,666 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $25.0k | 86,193 | | Added +28,830 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $22.3k | 77,005 | | Added +52,642 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $18.0k | 62,188 | | Reduced −11,692 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $9.9k | 34,280 | | New +34,280 | | [TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC](/funds/1849497.md) | 2026-06-30 | $3.8k | 13,000 | | Unchanged | | [TWO SIGMA SECURITIES, LLC](/funds/1450144.md) | 2026-06-30 | $3.8k | 12,953 | | New +12,953 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.7k | 12,854 | | Unchanged | ## Recent filings [All 541 filings](/companies/ensc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 01:56 ET | [8-K/A](/filings/0001493152-26-047317.md) | 9.01 Financial statements and exhibits | 0001493152-26-047317 | | 2026-09-29 | 12:31 ET | [8-K](/filings/0001493152-26-044802.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-044802 | | 2026-08-25 | 21:12 ET | [8-K](/filings/0001493152-26-040080.md) | 8.01 Other events | 0001493152-26-040080 | | 2026-08-24 | 21:13 ET | [8-K](/filings/0001493152-26-039898.md) | 8.01 Other events | 0001493152-26-039898 | | 2026-08-18 | 16:30 ET | [SCHEDULE 13D/A](/filings/0001493152-26-038943.md) | Ownership report, active investor, amended | 0001493152-26-038943 | | 2026-08-13 | 20:31 ET | [10-Q](/filings/0001493152-26-037817.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037817 | | 2026-08-13 | 20:20 ET | [8-K](/filings/0001493152-26-037794.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037794 | | 2026-08-06 | 19:45 ET | [8-K/A](/filings/0001493152-26-036326.md) | 9.01 Financial statements and exhibits | 0001493152-26-036326 | | 2026-08-06 | 12:20 ET | [8-K](/filings/0001493152-26-036268.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036268 | | 2026-07-15 | 20:15 ET | [8-K](/filings/0001493152-26-033360.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-033360 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013633.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1b4a5597-52dc-4af9-bfee-481bc0f79daa) ## About the filer - CIK: 1716947 - Tickers: ENSC - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.